Benefits of the programme include access to the Babraham Research Campus bio-incubator facilities, an extended programme of mentoring and support and £10k undiluted funding
News
Cambridge, UK., 21 September 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart, NovoRapid®, and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual meeting which will be held from 21-25 September 2020. Abstract #55 is available online.
Growth continues at Discovery Park as new tenants arrive
Psyros Diagnostics & VisusNano join innovation community
Sandwich, Kent, September 21 2020 – The innovation community is continuing to evolve at Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, as new tenants move in and others continue to develop. New entrants Psyros Diagnostics and VisusNano have both taken laboratory and office space at the Park.
StemFit® for Mesenchymal Stem Cells (MSC) is the latest addition to the StemFit® family of stem cell media. It is a chemically defined and human/animal origin free medium, optimized for the isolation and culture of MSCs from bone marrow (BM-MSC), umbilical cord (UC-MSC), and adipose (ADSC) under serum-free, human platelet lysate free conditions.
Pharmaceutical and biotech product development consultancy Boyds has recruited Kathryn Bartley as Senior Clinical Research Associate.
The appointment follows last year’s acquisition of Blue Duck Consultancy which fueled the expansion of Boyds’ in-house clinical and medical affairs services offering.
Kathryn has over 18 years’ experience in the industry, primarily in study and site management and monitoring. Her work has covered a variety of therapy areas across all trial phases within both the commercial and academic sectors.
Cambridge, UK, 08 September 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has significantly enhanced its global business development capabilities, with additional resources now committed to support key regions in the USA, Europe and Japan.
Cambridge, UK, and Cambridge, MA, 08 September 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and XtalPi Inc., a leading algorithm-driven artificial intelligence (AI)-based pharmaceutical technology company, today announced they have entered into a drug discovery collaboration agreement. Financial details are not disclosed.
CAMBRIDGE, UK 09 September 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced a collaboration with leading, global high-performance analog technology company, Analog Devices, Inc. The companies will work together on the advancement and commercial scale-up of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips and accelerate the development of Evonetix’s first product, a DNA desktop writer.
- TTP will provide entrepreneurs with mentoring and tech consultancy, to accelerate product development and commercialisation
- Agreement underlines TTP’s commitment to sharing knowledge and experience with innovative start-ups
- TTP to deliver virtual seminar on 17 September as part of Start Codon and Cancer Research UK’s Entrepreneurial Training Scheme